Browse Category

NYSE:ANET News 5 November 2025 - 29 November 2025

Arista Networks (ANET) Stock: AI Networking Leader Faces Insider Selling and Big Money Moves – 29 November 2025 Update

Arista Networks (ANET) Stock: AI Networking Leader Faces Insider Selling and Big Money Moves – 29 November 2025 Update

Arista Networks, Inc. (NYSE: ANET) remains one of the purest ways to invest in AI data‑center infrastructure. On 29 November 2025, fresh 13F filings, insider transactions, and new analyst commentary are giving investors an updated view of where this high‑growth networking stock might go next. Arista Networks Stock Snapshot: Price, Performance and Valuation Arista Networks has been on a powerful multi‑year run as cloud and AI data‑center demand exploded. According to recent analysis republished by Nasdaq, Arista’s share price is “around $125,” down from an all‑time high near $165 set in late October. The stock is still up about 13%
29 November 2025
Arista Networks Stock Today (ANET), November 23, 2025: AI Networking Leader Pulls Back, But Wall Street Still Sees Upside

Arista Networks Stock Today (ANET), November 23, 2025: AI Networking Leader Pulls Back, But Wall Street Still Sees Upside

As investors wake up this Sunday, November 23, 2025, Arista Networks (NYSE: ANET) is coming off another volatile week that capped a sharp November correction in one of the market’s premier AI infrastructure names. On Friday, November 21, Arista Networks’ stock closed at $117.43, down 1.81% on the day. That move left shares lower by 10.61% over the last five trading days, down 25.53% so far in November, but still up about 6.2% year to date and 15.6% over the past 12 months. AInvest Despite that painful short‑term slide, Arista still commands a market capitalization of roughly $148 billion, based
23 November 2025
Arista Networks Stock Skyrockets 40% YTD on AI Boom – But Q3 Guidance Triggers Pullback

Arista Networks Stock Skyrockets 40% YTD on AI Boom – But Q3 Guidance Triggers Pullback

Stock Performance & Technical Analysis Arista’s stock price has been on a tear in 2025, buoyed by investor enthusiasm for AI and cloud infrastructure plays. As of November 5, 2025, ANET traded around the mid-$150s per share, up roughly 40% year-to-datextb.com. This surge far outpaced the broader market, reflecting Arista’s pivotal role in powering AI data centers. In fact, even after a post-earnings drop, the stock was almost 39% higher in 2025 to date – a return well ahead of the S&P 500’s ~15% gainsiliconangle.com. However, shares pulled back sharply (about 12–13%) in early November after the company’s Q3 results.
5 November 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop